There are two or three areas I can think of right now. One example is that most intensivists think we really need to have a system whereby we can have a real-time understanding of what the bed situation is and where the bed stresses are across the country, particularly in a pandemic. Right now we don't even know how many ventilator-capable ICU beds there are across the country. We're trying to collect that information. The Canadian Critical Care Trials Group is doing that, but real-time intelligence to allow you to redeploy resources to hot spots if you need to doesn't exist. We have no hope of doing that right now. The development of a system like that is important.
There are other important issues along the same lines. You may not know it, but the funding that exists does not actually fund therapies that are close. For example, in the case of hyperimmune globulin therapy, which I think is by far the most likely unapproved therapy to be useful in critically ill patients, we're struggling to find development funding because there's no mechanism for it. You go to pharmaceutical companies and try to find some money and try to figure out a way to get it done, but federal funding and that kind of thing....
For example, the WHO has said that one of the key questions is to find out whether standard-dose antivirals or high-dose antivirals are more effective. There are all these very practical things. Another example is just looking at the testing to see how effective it is. These are very practical, immediate things, but to a great extent the mechanisms for funding them don't exist.